ND0701
a novel, stable, and less acidic formulation of apomorphine designed to overcome the complex usability and local site reactions observed with other apomorphine formulations for treating Parkinson’s disease (PD)
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Nemas, Mara:
1 article
(01/2017)
|
2. | Nyska, Abraham:
1 article
(01/2017)
|
3. | Ramot, Yuval:
1 article
(01/2017)
|
4. | Rubinski, Anna:
1 article
(01/2017)
|
5. | Schiffenbauer, Yael S:
1 article
(01/2017)
|
6. | Shaltiel-Karyo, Ronit:
1 article
(01/2017)
|
7. | Tsarfati, Yonit:
1 article
(01/2017)
|
8. | Weinstock, Irena:
1 article
(01/2017)
|
9. | Yacoby-Zeevi, Oron:
1 article
(01/2017)
|
10. | Zawoznik, Eduardo:
1 article
(01/2017)
|
Related Diseases
Related Drugs and Biologics